FIGURE 5.

Rituximab‐resistant diffuse large B‐cell lymphoma (DLBCL) cells show a metabolic shift of active glycolysis and oxidative phosphorylation (OXPHOS). A‐C, Glucose consumption (A), lactate production (B), and ATP levels (C) in R‐CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)‐resistant DLBCL cell line SU‐DHL‐2/R and rituximab‐resistant DLBCL cell line OCI‐ly8/R, as well as their parental cell lines. D, E, Cellular oxygen consumption rate (OCR) (D) or extracellular acidification rate (ECAR) (E) of SU‐DHL‐2/R and SU‐DHL‐2 cells was determined. F, Percent contribution of glycolysis and mitochondrial metabolism to total cellular ATP of SU‐DHL‐2/R and parental cells according to energy budget calculations. FCCP, carbonyl cyanide p‐trifluoromethoxyphenylhydrazone. **P < .01, ***P < .001